Navigation Links
Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007
Date:1/31/2008

ed to a net loss from continuing operations of $170 million, or a loss of $0.09 per diluted share for the same period in 2006. The 2007 results include charges of $292 million associated with the implementation of the previously announced Productivity Transformation Initiative, an in-process research and development charge of $230 million in connection with the acquisition of Adnexus Therapeutics (Adnexus) and an impairment charge of $275 million on the company's investments in auction rate securities. On a non- GAAP basis excluding specified items, fourth quarter 2007 net earnings from continuing operations were $654 million, or $0.33 per diluted share, compared to $344 million, or $0.18 per diluted share for the same period in 2006.

On January 8, 2008, the company completed the sale of its Medical Imaging business for approximately $525 million, which is presented as a discontinued operation. Included in discontinued operations were fourth quarter net sales of $142 million and $156 million in 2007 and 2006, respectively, and basic and diluted earnings per share of $0.02 in the fourth quarters of 2007 and 2006.

"We are moving forward with important strategic actions that are helping us advance our pipeline, increase productivity and transform to a Next Generation BioPharma company," said James M. Cornelius, chief executive officer, Bristol-Myers Squibb. "Our underlying operating performance this quarter was strong, demonstrating the power of our medicines to help even more people prevail in their fight against serious diseases. The sale of Medical Imaging has strengthened our ability to consider future acquisitions that add to our capabilities, portfolio and pipeline of biotech and specialty medicines. And our Productivity Transformation Initiative, which helps identify ways to operate more efficiently, has spawned a new culture of continuous improvement."

For the twelve months ended December 31, 2007, net sales from continuing operations incre
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related medicine news :

1. Avista Capital Partners Completes Acquisition of Bristol-Myers Squibb Medical Imaging
2. Bristol-Myers Squibb Names Alan J. Lacy to Board of Directors
3. Exelixis to Receive Milestone Payment From Bristol-Myers Squibb for Achievement of Liver X Receptor Agonist Development Milestone
4. ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan
5. Pharmacopeia Acquires Selective Androgen Receptor Modulator (SARM) Program from Bristol-Myers Squibb
6. Bristol-Myers Squibb to Announce Results for the Third Quarter of 2007 on October 25
7. Bristol-Myers Squibb Finalizes Settlement of Previously Disclosed Federal Investigation into Pricing, Sales and Marketing Practices
8. Jeremy Levin Joins Bristol-Myers Squibb as Senior Vice President of External Science, Technology and Licensing
9. Bristol-Myers Squibb Announces Dividend
10. P&G Reports $0.98 EPS, Up 17%, on 9% Sales Growth; Announces Plan to Create Stand-Alone Coffee Company
11. First Pharmaceutical Company Comes to Hoboken, NJ: Swiss-Based Octapharma to Move U.S. Headquarters to SJP Properties Waterfront Corporate Center II
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2015)... 28, 2015 In recent years Medical Marijuana ... practicing physicians as a way for them to expand their ... Cannabis as medicine. Since the FDA still lists Cannabis as ... available to licensed physicians that can help guide them ... Deborah Malka in Santa Cruz, CA is a leader ...
(Date:2/28/2015)... OR (PRWEB) February 28, 2015 In ... Duncan Fletcher of Game Change Athlete ... Shannon Leinert about the benefits of athlete development and ... some of the unique challenges that athletes face and ... and future success. , Fletcher became involved in athlete ...
(Date:2/28/2015)... February 28, 2015 With their commitment ... has added an additional exercise to their already robust ... exercise is most commonly known as, is often performed ... Pulls” are executed in a relatively safe manner and ... strength levels. The full description of “Rope Pulls” is ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 The ... is offering a new special. Throughout all of ... , This service can help ... problems and pain. Patients may notice certain symptoms that ... relining. These symptoms include: , 1.    Pain, clicking, and ...
(Date:2/28/2015)... Mew and Company, a Vancouver corporate tax ... business consulting services in addition to a variety of ... succession planning. Company finances are a complicated matter that ... of this, complex Canadian tax laws can make it ... result, Mew and Company works to advise their clients ...
Breaking Medicine News(10 mins):Health News:Reputable Cannabis Doctor In Santa Cruz and Monterey Joins the Medical Cannabis Network 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 3Health News:Classic Denture Center in Portland Oregon is Offering March Discount 2Health News:Vancouver Corporate Tax Accountants Now Provide Business Consulting Services 2
... , WEDNESDAY, Oct. 27 (HealthDay News) -- With ... expert offers breast cancer survivors some guidance on what ... Karen Syrjala, director of biobehavioral sciences and co-director ... Research Center in Seattle, touches upon both the lingering ...
... The brain,s inner network becomes increasingly more efficient as ... measures, a joint study from the Ecole Polytechnique Fdrale ... in collaboration with Harvard Medical School, has verified these ... the PNAS early online edition last week, the soon-to-be-released ...
... genes respond to hormonal changes and inflammation has been ... a five-year study. The research programme at the ... (BRC) is led by Professor Julian Davis, a consultant ... University of Manchester,s Developmental Biomedicine Research Group. He ...
... , TUESDAY, Oct. 26 (HealthDay News) --Middle-aged adults ... as a result of radiation exposure as younger adults ... thought to be more sensitive to the long-term impact ... runs counter to some previous research suggesting that as ...
... Institute in Melbourne, Australia, has been awarded a Victorian Cancer ... and highly lethal form of ovarian cancer. Epithelial ovarian ... the ovary, accounts for 90 per cent of ovarian tumours. ... research has revealed that it may start in cells outside ...
... though the cancer-treatment agent cetuximab is not considered effective ... research indicates that patients with colorectal cancer not responding ... who were treated with cetuximab had longer overall and ... a study in the October 27 issue of ...
Cached Medicine News:Health News:Women Urged to Reclaim Their Life After Breast Cancer 2Health News:The brain's journey from early Internet to modern-day fiber optics -- all in 1 lifetime 2Health News:Manchester team wins $1.9 million grant for 'cell control' study 2Health News:Cancer Risk From Radiation Doesn't Fade With Age 2Health News:VCA fellowship funding to extend ovarian cancer research 2Health News:Colorectal cancer patients with gene mutation show better response to cancer agent 2
(Date:2/27/2015)... 2015  Acsis Inc., the market leader for supply ... that John DiPalo , Acsis, Chief Strategy Officer, ... Chain Executive 2015 Provider Pro to Know. The ... to help prepare their companies, and customers, supply chains ... year,s list of Provider Pros to Know is featured ...
(Date:2/27/2015)... Feb. 27, 2015 Isis Pharmaceuticals, Inc. (Nasdaq: ... both its pro forma net operating loss (NOL) guidance ... strong financial position.  Isis, significantly improved financial results were ... million in payments the Company received from its partners.  ... was a nearly 60% improvement over its 2013 NOL ...
(Date:2/27/2015)... February 27, 2015 Report Details ... showing you trends, R&D progress, and predicted revenues ,Where ... What are the commercial prospects for this market and ... revenues and other trends to 2025, discussing data, opportunities ... you assess regenerative medicine : cell-based therapies that ...
Breaking Medicine Technology:Acsis CSO John DiPalo Named Supply & Demand Chain Executive 2015 Pro to Know 2Isis Reports Financial Results and Highlights for 2014 2Isis Reports Financial Results and Highlights for 2014 3Isis Reports Financial Results and Highlights for 2014 4Isis Reports Financial Results and Highlights for 2014 5Isis Reports Financial Results and Highlights for 2014 6Isis Reports Financial Results and Highlights for 2014 7Isis Reports Financial Results and Highlights for 2014 8Isis Reports Financial Results and Highlights for 2014 9Isis Reports Financial Results and Highlights for 2014 10Isis Reports Financial Results and Highlights for 2014 11Isis Reports Financial Results and Highlights for 2014 12Isis Reports Financial Results and Highlights for 2014 13Isis Reports Financial Results and Highlights for 2014 14Isis Reports Financial Results and Highlights for 2014 15Isis Reports Financial Results and Highlights for 2014 16Isis Reports Financial Results and Highlights for 2014 17Translational Regenerative Medicine: Market Prospects 2015-2025 2Translational Regenerative Medicine: Market Prospects 2015-2025 3Translational Regenerative Medicine: Market Prospects 2015-2025 4Translational Regenerative Medicine: Market Prospects 2015-2025 5Translational Regenerative Medicine: Market Prospects 2015-2025 6Translational Regenerative Medicine: Market Prospects 2015-2025 7Translational Regenerative Medicine: Market Prospects 2015-2025 8
... 2012  Boehringer Ingelheim will present results from LUX-Lung ... investigating afatinib in patients with stage IIIB or ... epidermal growth factor receptor (EGFR) mutation (EGFR M+), ... Society of Clinical Oncology (ASCO) in Chicago, June ...
... May 16, 2012  Leading events organiser UBM Conferences ... announced details of the forthcoming CPhI Extractables and Leachables ... 2pm IST/9:30am GMT/4:30pm CST. The free to attend webinar ... extractables and leachables and during drug development, in addition ...
Cached Medicine Technology:Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012 2Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012 3Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012 4Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012 5Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012 6Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012 7Global Webinar Focuses on Considerations for Extractables and Leachables 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: